• Share
  • Email
  • Print
Get Connected

Recent Anti-Bribery Allegations: A China Case Study - What Actions Should You Take to Protect Yourself and Your Company?

26 July 2013

On July 26, 2013 K&L Gates held the webinar "Recent Anti-Bribery Allegations: A China Case Study - What Actions Should You Take to Protect Yourself and Your Company?" 

Click here to view a recording of the webinar
Click here for presentation slides.
Click here for additional presentation materials.

Officials with China's Public Security Bureau (PSB) unveiled against pharmaceutical company, GlaxoSmithKline, allegations of bribery and misconduct and have launched an investigation. Four senior Chinese executives of GlaxoSmithKline’s China operations have been placed under arrest for alleged bribery of public officials and medical personnel, and a fifth executive (and UK national) was reportedly prevented from leaving the country.

As noted in a previous client alert, even if the charges here prove to be completely unfounded or based on a misunderstanding, they provide a sharp reminder for companies operating in China (and elsewhere) to pause and take stock of their efforts to avoid entanglement in corrupt activities.

Topics discussed included:

  • Insights into types of corruption enforcement actions brought against pharmaceutical companies by PRC authorities in the past
  • Analysis on possible actions/events that seem to have triggered this case and factors in the Chinese environment driving the position of the PSB
  • Implications for companies in the pharmaceutical medical device sector
  • Actions that companies should be taking now to mitigate risks and get ahead of the curve